1. Articles in category: News

    1-24 of 293 1 2 3 4 ... 11 12 13 »
    1. Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors or Lymphoma

      Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors or Lymphoma

      Conditions :   Childhood Solid Tumor;   Childhood Lymphoma Interventions :   Drug: Vinblastine;   Drug: Cyclophosphamide;   Drug: Capecitabine;   Drug: Nivolumab Sponsors :   Centre Oscar Lambret;   Anticancer Fund, Belgium;   Bristol-Myers Squibb Not yet recruiting

      Read Full Article
    2. Feasibility of High-dose Iodine-131-metaiodobenzylguanidine Therapy for High-risk Neuroblastoma Preceding Myeloablative Chemotherapy and Hematopoietic Stem Cell Transplantation: a Study Protocol.

      Feasibility of High-dose Iodine-131-metaiodobenzylguanidine Therapy for High-risk Neuroblastoma Preceding Myeloablative Chemotherapy and Hematopoietic Stem Cell Transplantation: a Study Protocol.

      Asia Ocean J Nucl Med Biol. 2018;6(2):161-166

      Authors: Araki R, Nishimura R, Inaki A, Wakabayashi H, Imai Y, Kuribayashi Y, Yoshimura K, Murayama T, Kinuya S

      Read Full Article
      Mentions: MIBG Chemotherapy
    3. Nanoparticles give immune cells a boost

      Nanoparticles give immune cells a boost

      ( Massachusetts Institute of Technology ) MIT researchers have devised a novel way to boost the effectiveness of T cell therapy against solid tumors. By attaching nanoparticle 'backpacks' carrying immune-stimulating drugs directly to T cells, the MIT engineers showed that they could enhance those T cells' response without inducing harmful side effects.

      Read Full Article
    4. Nanoparticles That Reshape the Tumor Milieu Create a Therapeutic Window for Effective T-cell Therapy in Solid Malignancies

      Nanoparticles That Reshape the Tumor Milieu Create a Therapeutic Window for Effective T-cell Therapy in Solid Malignancies

      A major obstacle to the success rate of chimeric antigen receptor (CAR-) T-cell therapy against solid tumors is the microenvironment antagonistic to T cells that solid tumors create. Conventional checkpoint blockade can silence lymphocyte antisurvival pathways activated by tumors, but because they are systemic, these treatments disrupt immune homeostasis and induce autoimmune side effects. Thus, new technologies are required to remodel the tumor milieu without causing systemic toxicities.

      Read Full Article
    5. Burkholderia Lethal Factor 1, a Novel Anti-Cancer Toxin, Demonstrates Selective Cytotoxicity in MYCN-Amplified Neuroblastoma Cells.

      Burkholderia Lethal Factor 1, a Novel Anti-Cancer Toxin, Demonstrates Selective Cytotoxicity in MYCN-Amplified Neuroblastoma Cells.

      Toxins (Basel). 2018 Jun 27;10(7):

      Authors: Rust A, Shah S, Hautbergue GM, Davletov B

      Abstract Immunotoxins are being investigated as anti-cancer therapies and consist of a cytotoxic enzyme fused to a cancer targeting antibody.

      Read Full Article
      Mentions: Antibody MYCN
    6. Pediatric Cancer Immunotherapy: Opportunities and Challenges.

      Pediatric Cancer Immunotherapy: Opportunities and Challenges.

      Paediatr Drugs. 2018 Jun 12;:

      Authors: Wedekind MF, Denton NL, Chen CY, Cripe TP

      Abstract Cancer immunotherapies, widely heralded as transformational for many adult cancer patients, are becoming viable options for selected subsets of pediatric cancer patients.

      Read Full Article
      Mentions: Immunotherapy
    7. Predictive Modeling of Neuroblastoma Growth Dynamics in Xenograft Model After Bevacizumab Anti-VEGF Therapy.

      Predictive Modeling of Neuroblastoma Growth Dynamics in Xenograft Model After Bevacizumab Anti-VEGF Therapy.

      Bull Math Biol. 2018 Jun 14;:

      Authors: He Y, Kodali A, Wallace DI

      Abstract Neuroblastoma is the leading cause of cancer death in young children. Although treatment for neuroblastoma has improved, the 5-year survival rate of patients still remains less than half.

      Read Full Article
      Mentions: Treatment
    8. New method to preserve boy cancer patient fertility being developed

      New method to preserve boy cancer patient fertility being developed

      Ben-Gurion University of the Negev (BGU) and Soroka University Medical Center researchers in Beer-Sheva, Israel are developing a cell culture system that for the first time can change testicular stem cells into sperm-like cells that may enable future fertility for boys with prepubertal cancer.

      Read Full Article
      Mentions: Genetics
    9. Immunotherapy for High-Risk Neuroblastoma: Management of Side Effects and Complications.

      Immunotherapy for High-Risk Neuroblastoma: Management of Side Effects and Complications.

      J Adv Pract Oncol. 2017 Jan-Feb;8(1):44-55

      Authors: Armideo E, Callahan C, Madonia L

      Abstract Despite more intensive therapy, high-risk neuroblastoma continues to be a challenging disease to treat. Postconsolidation immunotherapy has been studied for many years and has proven to be effective in clinical trials.

      Read Full Article
    10. Network Modeling of microRNA-mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN

      Network Modeling of microRNA-mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN

      Neuroblastoma is a pediatric cancer of the sympathetic nervous system where MYCN amplification is a key indicator of poor prognosis. However, mechanisms by which MYCN promotes neuroblastoma tumorigenesis are not fully understood. In this study, we analyzed global miRNA and mRNA expression profiles of tissues at different stages of tumorigenesis from TH-MYCN transgenic mice, a model of MYCN-driven neuroblastoma.

      Read Full Article
      Mentions: Imaging MYCN Genetics
    11. CureWorks Collaborative Launches to Accelerate Development of Immunotherapy Treatments for Childhood Cancers, Increase Access to Clinical Trials

      Seattle Children's, with participating members Children's National Health System, BC Children's Hospital and Children's Hospital Los Angeles, has launched CureWorks, an international collaborative of leading academic children's hospitals determined to accelerate the development of immunotherapy treatments for childhood cancer. CureWorks focuses on expanding immunotherapy trials and patient access around the world, as well as sharing data and collective expertise to advance novel cell therapies.

      Read Full Article
      Mentions: Immunotherapy
    12. President Signs STAR Act for Kids' Cancers.

      President Signs STAR Act for Kids' Cancers.

      Cancer Discov. 2018 Jun 07;:

      Authors:

      Abstract On June 5, President Donald Trump signed the Childhood Cancer Survivorship, Treatment, Access and Research Act, which aims to support pediatric cancer research by expanding the collection of patient biospecimens and records, improving surveillance, and investigating pediatric survivorship.

      PMID: 29880581 [PubMed - as supplied by publisher]

      Read Full Article
      Mentions: Treatment
    13. Erythropoietin enhances migration of human neuroblastoma cells: in vitro studies and potential therapeutic implications.

      Erythropoietin enhances migration of human neuroblastoma cells: in vitro studies and potential therapeutic implications.

      J Cancer Stem Cell Res. 2017;5:

      Authors: Poniewierska-Baran A, Rajewska-Majchrzak J, Ratajczak MZ

      Abstract The erythropoietin receptor (EpoR) is expressed by cells from the erythroid lineage; however, evidence has accumulated that it is also expressed by some other non-hematopoietic tissues including several solid tumor cells and proposed candidates for cancer stem cells. This is an important concern, because recombinant erythropoietin (EPO) is frequently employed in cancer patients as a drug to ameliorate anemia related to chemo/radiotherapy. In our studies, we employed three human neuroblastoma ...

      Read Full Article
      Mentions: Radiotherapy
    14. Rigorous study finds widely used treatment for infection fails young cancer patients

      A treatment designed to reduce bloodstream infections due to central venous catheters that had worked well in lab studies and is commonly used around the world, but had not been rigorously tested, failed to protect young cancer patients from recurring or...

      Read Full Article
      Mentions: Treatment
    1-24 of 293 1 2 3 4 ... 11 12 13 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles